Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. - Wikidata - awgldk - TriplyDB

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study.

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study.

http://www.wikidata.org/entity/Q51162001

about

Cost of disorders of the brain in Spain.Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany Plantarflexor weakness negatively impacts walking in persons with multiple sclerosis more than plantarflexor spasticity Multiple sclerosis spasticity daily management: retrospective data from Europe.Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.Spasticity in multiple sclerosis and role of glatiramer acetate treatment.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity Dynamometer-based measure of spasticity confirms limited association between plantarflexor spasticity and walking function in persons with multiple sclerosis.Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.Costs and quality of life in multiple sclerosis patients with spasticity.Multiple sclerosis spasticity epidemiology--key publications.Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions.Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.Estimate of the cost of multiple sclerosis in Spain by literature review.Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study.MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study.Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).Muscle elastography: a new imaging technique for multiple sclerosis spasticity measurement.

P2860

Q34062070-50302737-8DB3-4BCE-AAA2-70C9F4DF6801 Q34105894-DD4E22CE-BAE8-4E24-ABC7-4674F51213CE Q34125259-09D880DE-4D91-405F-AD4F-9DE370675687 Q34569824-8ADAA12B-9F6C-48EA-A3FA-794E12543E56 Q35577414-AFB9FB58-E93E-407B-8905-64FBD2C2B1C6 Q36109866-1C153E9D-9FB5-4278-A26E-394E659B5E11 Q36171531-7A28F3DC-3640-42D4-8BF8-0BB4FF29268B Q37235845-39B903B8-BF9A-40B4-8D18-19AF93CD23F5 Q37662068-10F6701C-76EE-436E-BD5A-EA22A02EF140 Q38003185-99ADD414-33C6-4B17-ABE5-EC0E577198C0 Q38003186-17034822-8256-4747-A7AA-D6BE8C1232A7 Q38078055-CD41AE31-743D-428F-B0DD-5A01062E1624 Q38107557-C10AC157-3545-4405-90B3-BE83AC6115CA Q38167395-7B5844F3-B08E-4AA4-A3D6-0327D6B166DB Q38256059-40A858EC-1E7C-494B-9BD0-142C10CDF909 Q38545685-820ACB3F-AE57-4098-9DA0-B90612EC74A8 Q38649249-1F7B3432-EF57-4F52-A828-1F00A96EF600 Q38649267-0ECA438A-F1DC-4D81-A8A3-0FA542BB35AB Q38682177-3C0C3DF0-733E-4BE6-95C3-E90F58CD5D12 Q39150365-AE5035B7-2203-4DC2-92CF-5C9EE4B75519 Q39447194-B55AAECB-688B-4857-BC73-9A58309FCA5F Q45091733-EBBBCDC0-E24F-4B91-8BEA-C767CDA96B26 Q48055428-A4CB43EA-7FC1-4029-AE66-E437EB601919 Q48125672-A9B44685-6F2D-4DDA-A8AD-829330E19624 Q48186758-7B9BD864-60F8-46EF-B47C-3ABFF869D32A

P2860

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study.

http://www.wikidata.org/entity/Q51162001

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Retrospective observational st ...... city in Spain: the '5E' study.

@en

Retrospective observational st ...... city in Spain: the '5E' study.

@nl

type

label

Retrospective observational st ...... city in Spain: the '5E' study.

@en

Retrospective observational st ...... city in Spain: the '5E' study.

@nl

prefLabel

Retrospective observational st ...... city in Spain: the '5E' study.

@en

Retrospective observational st ...... city in Spain: the '5E' study.

@nl

P1433

Q51162001-9E0A5098-06E5-40B2-BDF6-028E9E911FA5

P1476

Q51162001-531161F0-13DC-423D-B4A8-2239CE21D034

P2093

Q51162001-0BE2D10E-2952-4BB9-9FE0-C8FA469D6B5D

Q51162001-9A46C13A-F2D7-4EE2-A8A7-F1ACDA851B59

Q51162001-ECACA1D1-A3DE-448E-8B44-069A845A4DC8

P2860

Q51162001-125D1F7A-0C56-4B39-BA6E-A45F27DBBDDA

Q51162001-1A430F90-E3DD-4406-9390-13C53DE6B1A7

Q51162001-4E11E5AA-2148-497B-9E2A-C779B8895E68

Q51162001-611AB28E-1D21-4DDB-AB3A-793599E54A8D

Q51162001-710E4AEC-B948-4A86-93F3-7148274F057C

Q51162001-8671560B-0229-418E-B989-EA262325EC08

Q51162001-88E582C5-EB5E-491C-915D-76B553794C1C

Q51162001-9197BB68-1A5D-4ED5-AE29-0491C96D522D

Q51162001-A7A63FE0-3116-4AFB-B3AD-005BD28BB6A1

Q51162001-D3805B17-E358-45DC-8B44-5EDF355BAD8B

P304

Q51162001-58557FFD-4372-4AD0-8E00-D1FCADE82949

P31

Q51162001-670F39FC-FA40-418F-9CE8-C287DD0AAD95

P356

Q51162001-4F2F0306-6372-445C-B21B-F05C2637CE0B

P433

Q51162001-1DF53A3C-A1BE-44A4-AAC1-34E4BFDDFAD3

P478

Q51162001-3D71232C-7FCE-469B-A6D0-E975E5075867

P577

Q51162001-788B84A6-23C5-412E-844A-909B88B6BF1E

P698

Q51162001-CCF3360A-FD28-4FFD-911C-0C049F169CD3

P921

Q51162001-8260D271-F3EA-4C43-AFAD-6E102D5C6927

Q51162001-8330D479-D986-4B19-8481-436E40F9ED18

P356

P1433

Expert Review of Pharmacoeconomics & Outcomes Research

P1476

Retrospective observational st ...... city in Spain: the '5E' study.

@en

P2093

Carlos Vila

http://www.w3.org/2001/XMLSchema#string

Rafael Arroyo

http://www.w3.org/2001/XMLSchema#string

Steve Clissold

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Costs and quality of life of patients with multiple sclerosis in Europe

Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).

Pharmacoeconomic considerations in the treatment of multiple sclerosis.

Treatment of spasticity with botulinum toxin: a double-blind study.

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.

Rehabilitation in practice: Spasticity management.

Prevalence and treatment of spasticity reported by multiple sclerosis patients.

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis.

P304

205-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERP.11.6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21476822

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis